The effect of nine monoclonal antibodies to complement component C8 on the interaction of C9 with preformed cell-surface C5b-8 complexes and on the functional insertion of C8 into the membrane-attack complex (MAC) was investigated. None of the antibodies prevented C9 insertion into a preformed C5b-8 complex. One antibody (Fl) directed to the C8a subunit clearly inhibited formation of a functional MAC.
INTRODUCTION
The assembly of the membrane-attack complex (MAC), which is composed of the five terminal complement components, is initiated by proteolytic cleavage of C5 to C5a and C5b, followed by the sequential addition to C5b of C6, C7, C8 and C9 (Muller-Eberhard, 1988) . The obligatory and specific sequential steps of MAC formation suggest that each intermediate complex expresses binding (receptor) sites for the components that precede and follow it in the sequence. The binding of C8 (a trimer of a, , and y subunits; Sodetz, 1988) to membrane-bound C5b-7 is mediated via its subunit (Monahan & Sodetz, 1981; Brickner et al., 1985; Stewart et al., 1987) . Although the primary role of the C5b-8 complex is to allow membrane insertion and polymerization of component C9 (Podack et al., 1982) , the nature of the molecular interaction between C8 and C9 still remains poorly understood. Solution binding studies have shown that the a-subunit of C8 forms a stable complex with C9 (Stewart & Sodetz, 1985) . Despite this observation, attempts to establish a direct interaction between C8 and C9 on target membranes by crosslinking experiments have failed (Monahan et al., 1983) . Tschopp et al. (1982a,b) and Esser et al. (1985) have shown that C9 inserts into either lipid bilayers made leaky by reducing surface pressure or into small unilamellar vesicles. These findings indicate that lipid bilayer perturbation by C5b-8 (McClosky et al., 1986 ) might play a major role in the insertion of C9 (Stanley et al., 1986; Stanley, 1988) .
In an attempt to study the role played by C8 in the formation of the MAC, monoclonal antibodies against the three polypeptide chains of C8 were raised and characterized . In the present paper we report the results of studies carried out using the monoclonal antibodies against C8 to interfere with the function of C8 in MAC formation.
EXPERIMENTAL
Mouse monoclonal antibodies to human C8 were described previously and were affinity purified on protein A using a Bio-Rad Maps II kit (Bio-Rad Laboratories, Watford, Herts., U.K.). Human C8 + C9 + C8-depleted normal human serum (NHS), C9-depleted NHS and C5b-9 complexes were prepared as previously described (Morgan et al., 1983; Tomlinson et al., 1989) .
Preparation of pigeon erythrocyte ghosts, loading with
Bucks., U.K.) and sensitizing of cells and ghosts with anti-erythrocyte antibodies were as previously described (Morgan et al., 1984 C8 antibodies, approx. 50 o inhibition of marker release was observed (Morgan et al., 1984) .
In experiments to test the effect of anti-C8 monoclonal antibodies on the functional insertion of C8 into the MAC, aliquots (10,l) of NHS were preincubated with the monoclonal antibodies (40 ,ug/ml final concn.) for 20 min at room temperature (20°C) before addition to antibody-sensitized erythrocytes or ghosts. Samples were taken at 0 and 15 min of subsequent incubation at 36°C, and the release of haemoglobin or ["4C]sucrose was measured. Again conditions were chosen such that incubation of NHS with the same amount of the anti-C9 monoclonal antibody M47 results in approx. 5000 inhibition of marker release.
Throughout the experiments erythrocytes and ghosts were resuspended and incubated in Medium A, which contained 140 mM-NaCl, 5 mM-KCl, 2 mM-MgCl2 and 10 mM-Tes, adjusted to pH 7.4 with NaOH.
Dot-blot immunoassay was as previously described , and protein was measured by the method of Lowry et al. (1951) , with bovine serum albumin as standard.
RESULTS
IgG monoclonal antibodies against each of the three polypeptide chains of C8 were used in functional studies to examine their effect on the assembly of the MAC. Screening experiments were carried out to examine whether any of the antibodies added to preformed cellsurface C5b-8 intermediates would inhibit the functional insertion of C9 and whether any of the antibodies added to soluble C8 would prevent its functional incorporation during MAC formation. Throughout the study the release of either haemoglobin from sensitized intact pigeon erythrocytes or ["4C]sucrose from resealed sensitized erythrocyte ghosts was used as an index of MAC formation.
In the first experiment sensitized pigeon erythrocyte intermediates (EAC1-8) were prepared and incubated with each of the anti-C8 antibodies. The release of markers was subsequently assessed upon addition of C9. None of the antibodies affected haemoglobin release from intact erythrocytes ( Complement membrane-attack complex different, but overlapping, epitope , and X63, a non-specific IgG, had no effect at concentrations up to 200 ,g/ml. When the concentration of IgG reached 300,ug/ml, X63 and L6 had a small (approx. 200%) inhibitory effect, but at this concentration the inhibition by antibody Fl was much more pronounced. The ability of each of the anti-C8 monoclonal antibodies to interact with preformed C5b-9 complexes was shown by dot-blot immunoassay. The ratio of binding to C8 compared with binding to C5b-9 containing an equivalent molar concentration of C8 was, for each antibody: A2, 1.48, Bl, 1.16; D5, 1.30; E2, 0.94; Fl, 1.85; KI, 1.17; L6, 1.22; JI, 1.23; Ml, 1.14 (mean for duplicate experiments in each case).
DISCUSSION
We have previously prepared ten monoclonal antibodies to human complement component C8 . The nine IgG antibodies used in the present study comprise two anti-C8,I antibodies, two anti-C8y antibodies and five anti-C8a antibodies. The latter were classified in four overlapping epitope groups by competitive binding assay. All of the antibodies used in the present study have been shown to react with preformed C5b-9 by dot-blot immunoassay and in some cases by immunofluorescence . Preliminary studies using (NH4)2SO4 fractions of ascites fluid containing anti-C8 monoclonal antibodies suggested that several of the antibodies might be capable of interfering with MAC formation (Abraha et al., 1986; Luzio et al., 1987) , but the present experiments using affinity-purified monoclonal antibodies showed that none can inhibit the insertion of C9 into preformed C5b-8 complexes. One anti-a antibody, coded Fl, clearly inhibited the release of markers when incubated wth serum prior to the activation of the complement cascade. In separate experiments to examine the effect of the anti-C8 antibodies on marker release from sensitized erythrocyte ghosts preincubated with C9-depleted NHS (GAC 1-8), no effects of any antibodies on marker release were seen , though it should be noted that marker release in such experiments is always low, approximately double that observed from sensitized ghosts (GA) alone.
An attractive hypothesis for the mechanism of action by which the Fl antibody blocks the release of markers when incubated with normal human serum prior to the initiation of complement activation is that it prevents the unfolding of C8a and its subsequent insertion into the target membrane. Fl inhibition of MAC formation is unlikely to be simply a steric effect, because L6, which binds to a different but overlapping epitope, has no equivalent blocking effect (Fig. 1) with present knowledge of the primary structure of terminal complement components, since these have considerable sequence similarity, and it is likely that the mechanism by which they unfold and become inserted into the target membrane is the same . The proposed mechanism for Fl action is analogous to the explanation of the ability of the anti-C9 antibody M34 to prevent unfolding and insertion of C9 into target membranes (Stanley et al., 1986; Marazziti et al., 1988) , though the latter antibody has been shown to act from the intracellular side of the plasma-membrane bilayer. Our data is consistent with antibody Fl preventing the C5b-8-induced disturbance of the phospholipid bilayer that may be necessary for the functional insertion of C9 into target membranes (Stanley et al., 1986; Stanley, 1988) . This study was supported by a project grant from the Arthritis and Rheumatism Council.
